Related Experiment Videos
Chronic hepatitis. Aetiology and current management
Insights
Chronic hepatitis treatment remains complex, with autoimmune, hepatitis B, and non-A, non-B (NANB) types requiring distinct approaches. Understanding viral markers and developing NANB assays are key to solving chronic hepatitis enigmas.
Area of Science:
- Hepatology
- Immunology
- Virology
Background:
- Chronic hepatitis presents diagnostic and therapeutic challenges, necessitating exclusion of specific causes like drugs, Wilson's disease, and alpha-1-antitrypsin deficiency.
- Post-exclusion, chronic hepatitis is categorized into autoimmune, hepatitis B, and non-A, non-B (NANB) types, all with immunological underpinnings.
- Autoimmune hepatitis is histologically subtyped into chronic persistent and chronic active hepatitis.
Purpose of the Study:
- To review the current understanding and treatment strategies for different forms of chronic hepatitis.
- To highlight the immunological basis of chronic hepatitis pathogenesis.
- To discuss advancements in diagnosing and managing hepatitis B and the challenges in NANB hepatitis.
Main Methods:
- Literature review of studies on chronic hepatitis classification and treatment.
- Analysis of diagnostic criteria and therapeutic interventions for autoimmune hepatitis, hepatitis B, and NANB hepatitis.
- Examination of serological markers, molecular probes (HBV-DNA), and viral co-infections in hepatitis B.
Main Results:
- Corticosteroids are indicated for chronic active hepatitis with cirrhosis or bridging necrosis, but contraindicated in hepatitis B virus infection.
- Hepatitis B virus (HBV) infection management involves antiviral agents and immunomodulation, especially when viral replication is evident (e antigen, DNA polymerase, HBV-DNA positive).
- Non-A, non-B (NANB) hepatitis remains poorly understood due to the lack of a specific assay, suggesting potential for multiple causative agents.
Conclusions:
- Effective management of chronic hepatitis depends on accurate etiological classification and tailored treatment strategies.
- Advances in understanding hepatitis B, including serological markers and molecular probes, have significantly improved knowledge.
- Development of an assay for NANB hepatitis is anticipated to resolve remaining enigmas in chronic hepatitis research.
Abstract:
The entity of chronic hepatitis has long been an enigma, and its treatment confusing. Recent studies have indicated the importance of excluding causes such as drugs, Wilson's disease and alpha 1-antitrypsin deficiency. After excluding such causes, there are 3 major groups--'autoimmune', hepatitis B, and non-A, non-B (NANB) in all of which an immunological basis for pathogenesis exists. The autoimmune group has been subdivided into a milder type (chronic persistent hepatitis) and a more severe type (chronic active hepatitis) on histological grounds. Corticosteroids are indicated in chronic active hepatitis if cirrhosis or bridging necrosis is present. However, corticosteroids are contraindicated in disease due to the hepatitis B virus where chronic active hepatitis correlates with the presence of replicating virus (serum positive for e antigen, DNA polymerase and HBV-DNA), and in such cases antiviral agents and immunomodulation are being studied. Very little is known about NANB hepatitis in the absence of an assay and there may be more than a single agent. In hepatitis B, the development of serological markers, molecular probes (HBV-DNA), natural animal hepatitis with near-identical viruses, and delta antigen (a virus requiring co-infection with hepatitis B) have all extended our knowledge so dramatically that it is hoped that the enigma of chronic hepatitis will be solved when an assay for NANB hepatitis becomes available.